Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermira Inc.

www.dermira.com

Latest From Dermira Inc.

First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.

Clinical Trials Dermatology

Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results

Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.

Financing Business Strategies

Dermira’s Lebrikizumab Data Set Up Atopic Dermatitis Showdown With Dupixent

Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.

Clinical Trials Dermatology

Galderma’s First-In-Class Biologic Chases Eczema Spoils

Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.

Clinical Trials Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Skintelligence Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dermira Inc.
  • Senior Management
  • Thomas G Wiggans, CEO
    Andrew Guggenhime, CFO
    Eugene A Bauer, MD, CMO
    Chris Griffith, Chief Business & Strategy Officer
    Luis Pena, PhD, Chief Dev. Officer
    Lori Lyons-Williams, Chief Commercial Officer
  • Contact Info
  • Dermira Inc.
    Phone: (650) 421-7200
    275 Middlefield Rd.
    Ste. 150
    Menlo Park, CA 94025
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register